TScan Therapeutics, Inc.
NASDAQ:TCRXBiotechnology
+$0.02 today
- Market cap
- $50.37M
- Beta
- 1.03
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$0.96
Volume 0.00M
Average 0.81M
TCRX Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
TScan Therapeutics, Inc.NASDAQ: TCRX
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses declines year over year
Q1 FY2026 other income / expenses of $473K fell 77.7% year over year, behind the -46.5% change in trailing-twelve-month other income / expenses. Sequentially, it fell 46.3% from the prior quarter. Over 3 fiscal years it compounded at +144.2% a year.
Context
- Other income / expenses amounted to 58.6% of revenue in FY2025, down 201.4 pp from a year earlier.
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -77.7% toward the trailing-twelve-month pace of -46.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 6.05M USD
- Year-over-year change
- -17.4%
- 4-year CAGR
- +340.9%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.05M | -17.4% |
| FY2024 | 2024-12-31 | 7.32M | +72.7% |
| FY2023 | 2023-12-31 | 4.24M | +921.7% |
| FY2022 | 2022-12-31 | 415K | +2493.8% |
| FY2021 | 2021-12-31 | 16K | — |
Other Income / Expenses vs competitors
How TCRX compares with its peers on the latest reported figures
- TCRX's LTM Mar 2026 other income / expenses of $4.4M is the 7th highest of the 10 companies compared; the peer median is $5.09M.
- Its year-over-year change of -46.5% is the 8th highest of 10, against a peer median of -3.2%.
- Other income / expenses amounts to 48.1% of revenue for TCRX, versus a peer median of 4.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $189.09M | +2976.4% | — | 285.8% | |
| LTM Mar 2026 | $8.51M | +48.5% | +125.8% | — | |
| LTM Mar 2026 | $5.35M | +16.3% | — | — | |
| LTM Mar 2026 | $5.34M | -44.5% | +19.2% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $5.09M | -46.1% | +60.9% | — |
| LTM Mar 2026 | $4.97M | -46.6% | +24.4% | — | |
| LTM Mar 2026 | $4.4M | -46.5% | +144.2% | 48.1% | |
| LTM Mar 2026 | $1.47M | -57.0% | -25.8% | — | |
| LTM Apr 2026 | $76.1K | +102.0% | — | 4.2% | |
| LTM Mar 2026 | -$675K | -3.2% | — | 0.3% | |
| Peer median (excluding TCRX) | $5.09M | -3.2% | +24.4% | 4.2% | |
Competitors are the stored peer set for TCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.14M | 13.54M | 21.05M | 2.82M | 10.33M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.87M |
| Gross Profit | 10.14M | 13.54M | 21.05M | 2.82M | 7.46M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 72.2% |
| Research & Development | 44.95M | 59.82M | 88.15M | 107.35M | 114.15M |
| Selling, General & Admin | 13.83M | 20.35M | 25.49M | 29.56M | 31.99M |
| Operating Expenses | 58.78M | 80.17M | 114.51M | 137.64M | 143.27M |
| Depreciation & Amortization | 3.33M | 5.14M | 5.36M | 4.11M | 2.87M |
| EBITDA | (45.3M) | (59.91M) | (80.1M) | (119.74M) | (124.13M) |
| EBITDA Margin | -446.7% | -442.6% | -380.5% | -4252.1% | -1202.2% |
| Operating Income | (48.64M) | (66.64M) | (93.46M) | (134.82M) | (135.81M) |
| Operating Margin | -479.6% | -492.3% | -444.0% | -4787.7% | -1315.4% |
| Interest Income | 16K | 1.59M | 8M | 12.07M | 8.82M |
| Interest Expense | 0 | 1.18M | 3.76M | 3.65M | 2.77M |
| Other Income / Expenses | 16K | 415K | 4.24M | 7.32M | 6.05M |
| Income Before Tax | (48.63M) | (66.22M) | (89.22M) | (127.5M) | (129.77M) |
| Pre-Tax Margin | -479.5% | -489.3% | -423.9% | -4527.7% | -1256.8% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (48.63M) | (66.22M) | (89.22M) | (127.5M) | (129.77M) |
| Net Margin | -479.5% | -489.3% | -423.9% | -4527.7% | -1256.8% |
| EPS (Basic) | (2.03) | (2.74) | (1.36) | (1.14) | (1.00) |
| EPS (Diluted) | (2.03) | (2.74) | (1.36) | (1.14) | (1.00) |
| Weighted Avg Shares | 23.91M | 24.05M | 65.6M | 111.99M | 129.86M |
| Weighted Avg Shares (Diluted) | 23.91M | 24.05M | 65.6M | 111.99M | 129.86M |
TScan Therapeutics, Inc.
NASDAQ:TCRX
Intrinsic Alpha fair value
Locked
Current Price
$0.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.